{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T21:05:28Z","timestamp":1747170328391,"version":"3.40.5"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T00:00:00Z","timestamp":1495756800000},"content-version":"vor","delay-in-days":145,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","respiratorycasereports.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine Case Reports"],"published-print":{"date-parts":[[2017]]},"DOI":"10.1016\/j.rmcr.2017.06.015","type":"journal-article","created":{"date-parts":[[2017,7,3]],"date-time":"2017-07-03T22:46:33Z","timestamp":1499121993000},"page":"87-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis"],"prefix":"10.1016","volume":"22","author":[{"given":"Anna","family":"Hirano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4069-3721","authenticated-orcid":false,"given":"Naomi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Iwato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6358-2560","authenticated-orcid":false,"given":"Wakako","family":"Daido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Funaishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayaka","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Deguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5112-5573","authenticated-orcid":false,"given":"Masaya","family":"Taniwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.rmcr.2017.06.015_bib1","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"9","key":"10.1016\/j.rmcr.2017.06.015_bib2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"4","key":"10.1016\/j.rmcr.2017.06.015_bib3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3324\/haematol.2014.115840","article-title":"Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I","volume":"100","author":"Verstovsek","year":"2015","journal-title":"Haematologica"},{"issue":"25","key":"10.1016\/j.rmcr.2017.06.015_bib4","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.rmcr.2017.06.015_bib5","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmcr.2017.06.015_bib6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.rmcr.2017.06.015_bib7","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/1078-0432.CCR-12-0284","article-title":"Molecular pathways: Jak\/STAT pathway: mutations, inhibitors, and resistance","volume":"19","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.rmcr.2017.06.015_bib8","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1086\/322597","article-title":"Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy","volume":"33","author":"Pappas","year":"2001","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.rmcr.2017.06.015_bib9","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1378\/chest.12-1604","article-title":"An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor","volume":"143","author":"Wysham","year":"2013","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.rmcr.2017.06.015_bib10","first-page":"901","article-title":"Pulmonary cryptococcosis in the setting of tofacitinib therapy for psoriasis","volume":"14","author":"Seminario-Vidal","year":"2015","journal-title":"J.\u00a0Drugs Dermatol."},{"key":"10.1016\/j.rmcr.2017.06.015_bib11","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/1756-0500-5-552","article-title":"Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report","volume":"5","author":"Colomba","year":"2012","journal-title":"BMC Res. Notes"},{"issue":"3","key":"10.1016\/j.rmcr.2017.06.015_bib12","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.jaad.2013.09.035","article-title":"Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment","volume":"70","author":"Tong","year":"2014","journal-title":"J.\u00a0Am. Acad. Dermatol."},{"issue":"7","key":"10.1016\/j.rmcr.2017.06.015_bib13","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJMc1302895","article-title":"Bilateral toxoplasmosis retinitis associated with ruxolitinib","volume":"369","author":"Goldberg","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"issue":"2","key":"10.1016\/j.rmcr.2017.06.015_bib14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00277-015-2532-7","article-title":"Cryptococcal meningoencephalitis associated with the long-term use of ruxolitinib","volume":"95","author":"Chen","year":"2016","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.rmcr.2017.06.015_bib15","first-page":"95","article-title":"Ruxolitinib for the treatment of myelofibrosis: its clinical potential","volume":"8","author":"Ostojic","year":"2012","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.rmcr.2017.06.015_bib16","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.4049\/jimmunol.1103455","article-title":"Protective immunity against pulmonary cryptococcosis is associated with STAT1-mediated classical macrophage activation","volume":"189","author":"Hardison","year":"2012","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.rmcr.2017.06.015_bib17","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.4049\/jimmunol.1400318","article-title":"STAT1 signaling is essential for protection against Cryptococcus neoformans infection in mice","volume":"193","author":"Leopold Wager","year":"2014","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.rmcr.2017.06.015_bib18","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1128\/IAI.00935-15","article-title":"STAT1 signaling within macrophages is required for antifungal activity against Cryptococcus neoformans","volume":"83","author":"Leopold Wager","year":"2015","journal-title":"Infect. Immun."},{"issue":"11","key":"10.1016\/j.rmcr.2017.06.015_bib19","first-page":"1299","article-title":"A\u00a0case of pulmonary cryptococcosis and pneumocystis pneumonia in a patient with rheumatoid arthritis","volume":"75","author":"Nagasaka","year":"2016","journal-title":"Jpn. J. Chest Dis."}],"container-title":["Respiratory Medicine Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007117301740?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213007117301740?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T12:51:10Z","timestamp":1535633470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213007117301740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":19,"alternative-id":["S2213007117301740"],"URL":"https:\/\/doi.org\/10.1016\/j.rmcr.2017.06.015","relation":{},"ISSN":["2213-0071"],"issn-type":[{"type":"print","value":"2213-0071"}],"subject":[],"published":{"date-parts":[[2017]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmcr.2017.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}